EMEA-002823-PIP01-20

Table of contents

Key facts

Active substance
Autologous T lymphocyte-enriched population of cells transduced with a lentiviral vector encoding a chimeric antigen receptor targeting human B cell maturation antigen with 4-1BB and CD3-zeta intracellular signalling domains (CT053)
Therapeutic area
Oncology
Decision number
P/0411/2020
PIP number
EMEA-002823-PIP01-20
Pharmaceutical form(s)
Suspension for infusion
Condition(s) / indication(s)
Treatment of Multiple Myeloma
Route(s) of administration
Intravenous use
Contact for public enquiries
CARsgen Therapeutics Corporation

E-mail: RegulatoryUS@carsgen.com
Tel: +1 3462939390

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating